DOCSLIB.ORG

PDE1B Antibody

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PDE1B Antibody Efficient Professional Protein and Antibody Platforms PDE1B Antibody Basic information: Catalog No.: UMA60393 Source: Mouse Size: 50ul/100ul Clonality: Monoclonal Concentration: 1mg/ml Isotype: Mouse IgG1 Purification: Protein A affinity purified Useful Information: WB:1:500-1:1000 IHC:1:50-1:200 Applications: FC:1:100-1:200 Reactivity: Human, Rat Specificity: This antibody recognizes PDE1B protein. Immunogen: Recombinant protein PDEs are key enzymes in signaling pathways that influence smooth muscle tone regulation. The PDE1 family are calmodulin-dependent (CaM-PDEs) that undergo stimulation through a calcium-calmodulin complex. Human PDE1B (PDE1B1) protein is present in neuronal cells of the cerebellum, hip- pocampus, and caudate, and lymphoblastoid lines, such as RPMI-8392 cells. Description: PDE1B may participate in learning, memory, and regulation of phosphoryla- tion of DARPP-32 in dopaminergic neurons. A splice variant known as PDE1B2 encodes a 516-amino acid protein and diverges from PDE1B1 by the replacement of the first 38 residues with an alternative 18 residues. The human PDE1B gene maps to chromosome 12q13, contains 13 exons, and encodes a 536 amino acid protein. Uniprot: Q01064(Human) Q01066(Rat) BiowMW: 61 kDa Buffer: 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. Storage: Store at 4°C short term and -20°C long term. Avoid freeze-thaw cycles. Note: For research use only, not for use in diagnostic procedure. Data: Gene Universal Technology Co. Ltd www.universalbiol.com Tel: 0550-3121009 E-mail: [email protected] Efficient Professional Protein and Antibody Platforms Western blot analysis of PDE1B on human PDE1B recombinant protein using anti-PDE1B antibody at 1/1,000 dilution. Western blot analysis of PDE1B on HEK293 (1) and PDE1B-hIgGFc transfected HEK293 (2) cell lysate using anti-PDE1B antibody at 1/1,000 dilu- tion. Western blot analysis of PDE1B on PC-12 cell ly- sate using anti-PDE1B antibody at 1/1,000 dilu- tion. Immunohistochemical analysis of paraf- fin-embedded human ovarian cancer tissue using anti-PDE1B antibody. Counter stained with he- matoxylin. Gene Universal Technology Co. Ltd www.universalbiol.com Tel: 0550-3121009 E-mail: [email protected] .
Load more

Recommended publications
  • Genome-Wide Analysis of Copy Number Variation Identifies Candidate Gene Loci Associated with the Progression of Non-Alcoholic Fatty Liver Disease
    Genome-Wide Analysis of Copy Number Variation Identifies Candidate Gene Loci Associated with the Progression of Non-Alcoholic Fatty Liver Disease Shamsul Mohd Zain1,2*, Rosmawati Mohamed3*, David N. Cooper4, Rozaimi Razali5, Sanjay Rampal6, Sanjiv Mahadeva3, Wah-Kheong Chan3, Arif Anwar5, Nurul Shielawati Mohamed Rosli5, Anis Shafina Mahfudz7, Phaik-Leng Cheah8, Roma Choudhury Basu9, Zahurin Mohamed1,2 1 The Pharmacogenomics Laboratory, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 2 Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 3 Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 4 Institute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom, 5 Sengenics Sdn Bhd, High Impact Reseach Building, University of Malaya, Kuala Lumpur, Malaysia, 6 Julius Centre University of Malaya, Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 7 Medical Imaging Unit, Faculty of Medicine, University of Technology MARA, Sungai Buloh Campus, Selangor, Malaysia, 8 Department of Pathology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 9 Clinical Investigation Centre, University Malaya Medical Centre, Kuala Lumpur, Malaysia Abstract Between 10 and 25% of individuals with non-alcoholic fatty liver disease (NAFLD) develop hepatic fibrosis leading to cirrhosis and hepatocellular carcinoma (HCC). To investigate the molecular basis of disease progression, we performed a genome-wide analysis of copy number variation (CNV) in a total of 49 patients with NAFLD [10 simple steatosis and 39 non- alcoholic steatohepatitis (NASH)] and 49 matched controls using high-density comparative genomic hybridization (CGH) microarrays. A total of 11 CNVs were found to be unique to individuals with simple steatosis, whilst 22 were common between simple steatosis and NASH, and 224 were unique to NASH.
    [Show full text]
  • Microrna-378 Controls Classical Brown Fat Expansion to Counteract Obesity
    ARTICLE Received 3 Jun 2014 | Accepted 17 Jul 2014 | Published 22 Aug 2014 DOI: 10.1038/ncomms5725 MicroRNA-378 controls classical brown fat expansion to counteract obesity Dongning Pan1, Chunxiao Mao1, Brian Quattrochi1, Randall H. Friedline2, Lihua J. Zhu1, Dae Young Jung2, Jason K. Kim2, Brian Lewis1 & Yong-Xu Wang1 Both classical brown adipocytes and brown-like beige adipocytes are considered as promising therapeutic targets for obesity; however, their development, relative importance and functional coordination are not well understood. Here we show that a modest expression of miR-378/378* in adipose tissue specifically increases classical brown fat (BAT) mass, but not white fat (WAT) mass. Remarkably, BAT expansion, rather than miR-378 per se, suppresses formation of beige adipocytes in subcutaneous WAT. Despite this negative feedback, the expanded BATdepot is sufficient to prevent both genetic and high-fat diet-induced obesity. At the molecular level, we find that miR-378 targets phosphodiesterase Pde1b in BAT but not in WAT. Indeed, miR-378 and Pde1b inversely regulate brown adipogenesis in vitro in the absence of phosphodiesterase inhibitor isobutylmethylxanthine. Our work identifies miR-378 as a key regulatory component underlying classical BAT-specific expansion and obesity resistance, and adds novel insights into the physiological crosstalk between BAT and WAT. 1 Program in Gene Function and Expression and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA. 2 Program in Molecular Medicine and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA. Correspondence and requests for materials should be addressed to Y.-X.W. (email: [email protected]).
    [Show full text]
  • Characterization and Antimicrobial Efficacy of Bovine Dermcidin, a Novel Antimicrobial Peptide Gene
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 6 May 2019 doi:10.20944/preprints201905.0037.v1 Article Characterization and antimicrobial efficacy of bovine dermcidin, a novel antimicrobial peptide gene Nevien M. Sabry1 and Tarek A. A. Moussa2* 1 Cell Biology Department, Genetic Engineering and Biotechnology Division, National Research Centre, Giza 12622, Egypt; [email protected] 2 Botany and Microbiology Department, Faculty of Science, Cairo University, Giza 12613, Egypt.; [email protected] * Correspondence: [email protected]; Tel.: +20-1001-531-738 Abstract: Description of a novel bovine antimicrobial peptide and its antimicrobial spectrum. RNA isolation and RT-PCR were done from various tissues. DCD peptide was synthesized, and antimicrobial activity was analyzed. Bovine dermcidin gene contains five exons intermittent by 4 introns. Bovine DCD-mRNA was 398 bp with ORF 336 bp. Bovine DCD was expressed in skin and blood. Analysis of the amino acid compositions revealed that cysteine was repeated 6 times indicating the presence of 3 disulfide bonds that play role in the peptide stability. Staphylococcus epidermidis, Streptococcus bovis, and Enterococcus faecalis were affected by Bovine DCD peptide. Highest antimicrobial effect was at 50 and 100 µg/ml. The effect on Escherichia coli and Candida albicans was slightly low. In all bacteria, Bovine DCD peptide activity did not affect by varying pH values, but in Staphylococcus aureus, the activity was affected greatly at pH 4.5 and 5.5. The optimum salt concentrations were 100 and 50 mM NaCl with all bacterial strains and E. coli, respectively. In case of C. albicans, the antimicrobial activity of Bovine DCD peptide decreased with increasing the pH value regardless the NaCl concentration.
    [Show full text]
  • Prognostic and Clinicopathological Insights of Phosphodiesterase 9A Gene As Novel Biomarker in Human Colorectal Cancer Tasmina Ferdous Susmi1†, Atikur Rahman1,2†, Md
    Susmi et al. BMC Cancer (2021) 21:577 https://doi.org/10.1186/s12885-021-08332-3 RESEARCH Open Access Prognostic and clinicopathological insights of phosphodiesterase 9A gene as novel biomarker in human colorectal cancer Tasmina Ferdous Susmi1†, Atikur Rahman1,2†, Md. Moshiur Rahman Khan1, Farzana Yasmin1, Md. Shariful Islam3,4*, Omaima Nasif5, Sulaiman Ali Alharbi6, Gaber El-Saber Batiha7 and Mohammad Uzzal Hossain8 Abstract Background: PDE9A (Phosphodiesterase 9A) plays an important role in proliferation of cells, their differentiation and apoptosis via intracellular cGMP (cyclic guanosine monophosphate) signaling. The expression pattern of PDE9A is associated with diverse tumors and carcinomas. Therefore, PDE9A could be a prospective candidate as a therapeutic target in different types of carcinoma. The study presented here was designed to carry out the prognostic value as a biomarker of PDE9A in Colorectal cancer (CRC). The present study integrated several cancer databases with in-silico techniques to evaluate the cancer prognosis of CRC. Results: The analyses suggested that the expression of PDE9A was significantly down-regulated in CRC tissues than in normal tissues. Moreover, methylation in the DNA promoter region might also manipulate PDE9A gene expression. The Kaplan–Meier curves indicated that high level of expression of PDE9A gene was associated to higher survival in OS, RFS, and DSS in CRC patients. PDE9A demonstrated the highest positive correlation for rectal cancer recurrence with a marker gene CEACAM7. Furtheremore, PDE9A shared consolidated pathways with MAPK14 to induce survival autophagy in CRC cells and showed interaction with GUCY1A2 to drive CRPC. Conclusions: Overall, the prognostic value of PDE9A gene could be used as a potential tumor biomarker for CRC.
    [Show full text]